Ingredients and solutions for the food industry
Microorganisms and active ingredients for human health
Lactic acid bacteria for the agri-veterinary sector

Unveiling the survivability of probiotic CA15 strain with and without fluconazole co-administration and its effect on gut microbiota and metabolome through SHIME® model

20/11/2025

“Survivability of probiotic CA15 strain with and without fluconazole co-administration and its effect on gut microbiota and metabolome through SHIME® model” is the title of the study that has been published recently which examines the behavior of the probiotic strain L. rhamnosus CA15 under simulated gastrointestinal conditions, including in the presence of the antifungal drug fluconazole.

Probiotic CA15: how does it behave in the gut and alongside drug treatments?

The study evaluated the ability of the probiotic L. rhamnosus CA15 to survive along the gastrointestinal tract and its impact on gut microbiota composition and the metabolome, using the dynamic in vitro SHIME® model, which simulates conditions in the human digestive system.

The researchers considered both fasted and fed conditions and also investigated co-administration of the antifungal fluconazole. The colonic phase was monitored for up to 24 hours, assessing the presence of the CA15 strain using a strain-specific RT-qPCR technique and, in parallel, analyzing microbiota (16S rRNA) and metabolome profiles.

Key findings

The results showed that:

  • Fasting conditions did not impair the survival of the CA15 strain in the ileal phase.
  • Co-administration of fluconazole did not reduce the viability of the probiotic.

However, fluconazole alone caused significant changes in the microbiota of the colonic fraction, including:

  • a reduction in the Firmicutes
  • an increase in the Proteobacteria

and a decrease in several genera, such as Dorea, Mitsuokella, Lactobacillus, Oscillospiraceae UCG-002, Bifidobacterium, as well as the Christensenellaceae_R-7_group and Eubacterium hallii.

When the CA15 strain was administered together with fluconazole in the colonic fraction, these antifungal-induced alterations were largely counteracted.

In addition, the presence of CA15 led to a significant increase in several beneficial metabolites, including volatile organic compounds and short- and branched-chain fatty acids, particularly heptanoic, acetic, propanoic, and isobutyric acids.

Conclusions

Overall, the L. rhamnosus CA15 strain showed:

  • good survivability along the simulated gastrointestinal tract, under both fasted and fed conditions
  • a positive modulatory effect on gut microbiota and the metabolome
  • the ability to help counterbalance microbial imbalances induced by fluconazole treatment

The use of the dynamic SHIME® model made it possible to gain valuable insights into the delivery and performance of the CA15 probiotic strain in the gastrointestinal tract, supporting its potential as a functional probiotic.

Read the full article here: https://www.sciencedirect.com/science/article/pii/S0963996925020952

Latest news

04 September 2026
CSL USA expands its probiotic manufacturing capabilities with integrated encapsulation and packaging

CSL USA Inc., a Sacco System company, is expanding its manufacturing facility in Franksville, Wisconsin, with new fully automated encapsulation and bottle packaging capabilities. The investment further strengthens CSL USA’s

19 March 2026
A regulatory achievement for Sacco System: our Heat-Inactivated CRL1505® receives GRAS status

An important regulatory goal has been achieved with the conclusion reached by an independent expert panel for the self-affirmed GRAS (Generally Recognized as Safe) determination of our postbiotic CRL1505® HI.

24 January 2026
SYNBIO: Sacco System's probiotic support for healthy ageing

The global population is ageing faster than ever before. In 2019, life expectancy at birth reached 72.8 years almost 9 years more than in 1990. In this context, staying healthy

22 December 2025
Sacco System grows in Latin America: BioInsumos in Uruguay and Sacco Brasil acquired.

The Group is accelerating its South American growth strategy through a twofold transaction: the acquisition of a Uruguayan company and the full absorption of its Brazilian subsidiary. The Group is

11 December 2025
Sacco System Presents PerforMilk®: Unlocking Milk’s Full Potential by Preserving Protein Quality 

Milk is the most precious resource in dairy production. High-quality dairy products start with high-quality milk—and in today’s rapidly evolving dairy landscape, protecting that quality has never been more critical. 

07 February 2025
Lacticaseibacillus rhamnosus CA15 Achieves GRAS Status: A Milestone for Women's Health

GRAS (Generally Recognised as Safe) is a designation by the US Food and Drug Administration (FDA) that indicates that a substance is considered safe based on expert consensus or a

08 January 2025
Sacco System Australia’s Heat-Inactivated Postbiotics Receive Positive Recommendations from FSANZ

Brisbane, 8 January 2025 Sacco System Australia, a leader in innovative probiotic and postbiotic solutions, is proud to announce that L. rhamnosus CRL 1505 HI (heat-inactivated) and Lactobacillus acidophilus LA1

25 November 2024
News
Our 2023 sustainability report is online!

We are proud to present the fifth edition of our Sustainability Report, an opportunity to reflect on the milestones achieved and the challenges ahead…

16 April 2024
News
Sacco System is pleased to announce the grand opening of its development site in Australia.

Today in the presence of Luna Angelini Marinucci, from 2022 the Consul of Italy in Brisbane, with territorial jurisdiction over the State of Queensland…

26 March 2024
News
Sacco System companies have been awarded as Sustainability champions by Ecovadis

At Sacco System we have always put Sustainability at the very core of our activities and our commitment, which is why we are proud that our companies Caglificio Clerici…

18 March 2024
News
List Biotherapeutics and Sacco System Announce Lead Share Agreement

List Biotherapeutics, Inc. (List Bio) and Sacco System Australia Pty Ltd (Sacco) today announced a lead share agreement…

26 February 2024
News
CSL FRANCE becomes SACCO SYSTEM FRANCE

Sacco System is the international biotechnological company dedicated to the food, nutraceutical, and pharmaceutical industries…